Switch theme
Sign up to access all valuation multiples
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China.
2009
567
LTM Revenue $119M
LTM EBITDA -$80.1M
$2.3B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Ascentage Pharma Group has a last 12-month revenue (LTM) of $119M and a last 12-month EBITDA of -$80.1M.
In the most recent fiscal year, Ascentage Pharma Group achieved revenue of $125M and an EBITDA of -$30.3M.
Ascentage Pharma Group expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Ascentage Pharma Group valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $119M | XXX | $125M | XXX | XXX | XXX |
| Gross Profit | $113M | XXX | $121M | XXX | XXX | XXX |
| Gross Margin | 95% | XXX | 97% | XXX | XXX | XXX |
| EBITDA | -$80.1M | XXX | -$30.3M | XXX | XXX | XXX |
| EBITDA Margin | -67% | XXX | -24% | XXX | XXX | XXX |
| EBIT | -$91.7M | XXX | -$47.2M | XXX | XXX | XXX |
| EBIT Margin | -77% | XXX | -38% | XXX | XXX | XXX |
| Net Profit | -$93.8M | XXX | -$51.7M | XXX | XXX | XXX |
| Net Margin | -79% | XXX | -41% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $51.3M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Ascentage Pharma Group's stock price is HKD 50 (or $6).
Ascentage Pharma Group has current market cap of HKD 17.5B (or $2.2B), and EV of HKD 17.9B (or $2.3B).
See Ascentage Pharma Group trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.3B | $2.2B | XXX | XXX | XXX | XXX | $-0.27 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Ascentage Pharma Group has market cap of $2.2B and EV of $2.3B.
Ascentage Pharma Group's trades at 18.3x EV/Revenue multiple, and -75.5x EV/EBITDA.
Equity research analysts estimate Ascentage Pharma Group's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Ascentage Pharma Group has a P/E ratio of -25.8x.
See valuation multiples for Ascentage Pharma Group and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2.2B | XXX | $2.2B | XXX | XXX | XXX |
| EV (current) | $2.3B | XXX | $2.3B | XXX | XXX | XXX |
| EV/Revenue | 20.9x | XXX | 18.3x | XXX | XXX | XXX |
| EV/EBITDA | -31.1x | XXX | -75.5x | XXX | XXX | XXX |
| EV/EBIT | -27.2x | XXX | -48.5x | XXX | XXX | XXX |
| EV/Gross Profit | 22.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | -25.8x | XXX | -43.1x | XXX | XXX | XXX |
| EV/FCF | -28.8x | XXX | -132.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAscentage Pharma Group's last 12 month revenue growth is 61%
Ascentage Pharma Group's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.3M for the same period.
Ascentage Pharma Group's rule of 40 is -273% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Ascentage Pharma Group's rule of X is 86% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Ascentage Pharma Group and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 61% | XXX | 60% | XXX | XXX | XXX |
| EBITDA Margin | -67% | XXX | -24% | XXX | XXX | XXX |
| EBITDA Growth | -74% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -273% | XXX | 37% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 86% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 20% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 97% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 135% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Ascentage Pharma Group acquired XXX companies to date.
Last acquisition by Ascentage Pharma Group was XXXXXXXX, XXXXX XXXXX XXXXXX . Ascentage Pharma Group acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Ascentage Pharma Group founded? | Ascentage Pharma Group was founded in 2009. |
| Where is Ascentage Pharma Group headquartered? | Ascentage Pharma Group is headquartered in Hong Kong. |
| How many employees does Ascentage Pharma Group have? | As of today, Ascentage Pharma Group has 567 employees. |
| Who is the CEO of Ascentage Pharma Group? | Ascentage Pharma Group's CEO is Dr. Dajun Yang, M.D.,PhD. |
| Is Ascentage Pharma Group publicy listed? | Yes, Ascentage Pharma Group is a public company listed on HKG. |
| What is the stock symbol of Ascentage Pharma Group? | Ascentage Pharma Group trades under 06855 ticker. |
| When did Ascentage Pharma Group go public? | Ascentage Pharma Group went public in 2019. |
| Who are competitors of Ascentage Pharma Group? | Similar companies to Ascentage Pharma Group include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Ascentage Pharma Group? | Ascentage Pharma Group's current market cap is $2.2B |
| What is the current revenue of Ascentage Pharma Group? | Ascentage Pharma Group's last 12 months revenue is $119M. |
| What is the current revenue growth of Ascentage Pharma Group? | Ascentage Pharma Group revenue growth (NTM/LTM) is 61%. |
| What is the current EV/Revenue multiple of Ascentage Pharma Group? | Current revenue multiple of Ascentage Pharma Group is 20.9x. |
| Is Ascentage Pharma Group profitable? | Yes, Ascentage Pharma Group is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Ascentage Pharma Group? | Ascentage Pharma Group's last 12 months EBITDA is -$80.1M. |
| What is Ascentage Pharma Group's EBITDA margin? | Ascentage Pharma Group's last 12 months EBITDA margin is -67%. |
| What is the current EV/EBITDA multiple of Ascentage Pharma Group? | Current EBITDA multiple of Ascentage Pharma Group is -31.1x. |
| What is the current FCF of Ascentage Pharma Group? | Ascentage Pharma Group's last 12 months FCF is -$86.4M. |
| What is Ascentage Pharma Group's FCF margin? | Ascentage Pharma Group's last 12 months FCF margin is -72%. |
| What is the current EV/FCF multiple of Ascentage Pharma Group? | Current FCF multiple of Ascentage Pharma Group is -28.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
